Back to Browse Journals » ClinicoEconomics and Outcomes Research » Volume 1

Management strategies and cost effectiveness in the prevention of cervical cancer

Authors Smita R Prasad

Published Date June 2009 Volume 2009:1 Pages 17—23

DOI http://dx.doi.org/10.2147/CEOR.S4226

Published 5 June 2009

Smita R Prasad

University of Kentucky, College of Public Health, Lexington, KY, USA

Abstract: This paper introduces the burden of cervical cancer and the primary and secondary preventative interventions currently available, and provides an overview of the bivalent and quadrivalent human papillomavirus (HPV) vaccines. A brief account of the virology and the clinical efficacy of both is given. Examinations of the two main types of cost analyses, cost-effective and cost-benefit, as well as examples, are presented in addition to the possible impact these analyses and further economic models will have on budget and policy making decisions. In general, most cost analyses provide support for the implementation of primary prevention strategies, HPV immunization, in conjunction with cervical cancer screening programs. Vaccination against HPV, therefore, is a cost-effective cervical cancer prevention mechanism.

Keywords: cervical cancer, human papillomavirus, HPV

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Mécano-Stimulation™ of the skin improves sagging score and induces beneficial functional modification of the fibroblasts: clinical, biological, and histological evaluations

Humbert P, Fanian F, Lihoreau T, Jeudy A, Elkhyat A, Robin S, Courderot-Masuyer C, Tauzin H, Lafforgue C, Haftek M

Clinical Interventions in Aging 2015, 10:387-403

Published Date: 2 February 2015

Managing comorbidities in COPD

Hillas G, Perlikos F, Tsiligianni I, Tzanakis N

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:95-109

Published Date: 7 January 2015

Leading teams during simulated pediatric emergencies: a pilot study

Coolen EH, Draaisma JM, den Hamer S, Loeffen JL

Advances in Medical Education and Practice 2015, 6:19-26

Published Date: 6 January 2015

Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus

Okuma Y, Hosomi Y, Imamura A

OncoTargets and Therapy 2015, 8:111-115

Published Date: 31 December 2014

Lebrikizumab in the personalized management of asthma

Thomson NC, Patel M, Smith AD

Biologics: Targets and Therapy 2012, 6:329-335

Published Date: 14 September 2012

Lack of information and access to advanced treatment for Parkinson’s disease patients

Lökk J

Journal of Multidisciplinary Healthcare 2011, 4:433-439

Published Date: 13 December 2011

Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy

Gerald HJ Mickisch, Björn Schwander, Bernard Escudier, et al

ClinicoEconomics and Outcomes Research 2011, 3:19-27

Published Date: 25 January 2011

Inpatient charges and mental illness: Findings from the Nationwide Inpatient Sample 1999–2007

Jim E Banta, Ivorie Belk, Kedon Newton, et al

ClinicoEconomics and Outcomes Research 2010, 2:149-158

Published Date: 11 October 2010